中国妇幼保健

目的 探究康妇炎胶囊联合抗生素治疗盆腔炎性疾病(PID)盆腔痛的临床相关，分析对患者中医证候积分和炎症细胞因子水平的影响。方法 选取2022年10月—2025年2月在杭州市临平区妇幼保健院就诊的180例PID盆腔痛患者，随机分为对照组、短期药物组及长期药物组，每组各60例。对照组给予头孢地尼胶囊治疗，短期药物组在对照组基础上加用康妇炎胶囊28 d,长期药物组在对照组基础上加用康妇炎胶囊56 d。比较3组临床疗效、中医证候积分、C-反应蛋白(CRP)、白细胞介素-6(IL-6)水平、白细胞介素-10(IL-10)水平及不良反应发生率。结果 治疗后，短期药物组(90.00%)和长期药物组(95.00%)总有效率均高于对照组(75.00%),差异均有统计学意义(χ²=4.675、9.412,均P<0.05),但短期药物组和长期药物组总有效率比较差异无统计学意义(χ²=1.081,P>0.05)。短期药物组主症评分[(3.24±0.89)分]、次症评分[(3.12±0.84)分]均低于对照组[主症(5.37±1.16)分、次症(4.78±0.95)分],差异均有统计学意义(t=11.280、10.140,均P<0.05);长期药物组主症评分[(3.07±0.72)分]、次症评分[(2.74±0.71)分]均低于对照组(t=13.050、13.320,均P<0.05),且长期药物组次症评分低于短期药物组(t=2.676,P<0.05)。短期药物组的CRP水平[(5.12±1.86)mg/L]、IL-6水平[(14.42±3.75)pg/ml]低于对照组[CRP(8.25±2.41)mg/L、IL-6(20.16±4.38)pg/ml](t=7.964、7.711,均P<0.05),IL-10水平[(29.84±5.16)pg/ml]高于对照组[(24.35±4.52)pg/ml],差异有统计学意义(t=6.199,P<0.05);长期药物组的CRP水平[(3.85±1.24)mg/L]、IL-6水平[(10.26±3.02)pg/ml]均低于对照组(t=12.580、14.410,均P<0.05),IL-10水平[(33.74±5.86)pg/ml]高于对照组(t=9.828,P<0.05);且长期药物组的CRP、IL-6水平均低于短期药物组(t=4.401、6.692,均P<0.05),IL-10水平高于短期药物组(t=3.869,P<0.05)。对照组、短期药物组及长期药物组不良反应发生率比较差异无统计学意义(χ²=1.084,P>0.05)。结论 康妇炎胶囊联合抗生素治疗PID盆腔痛疗效显著，可提高总有效率、降低中医证候积分、改善炎症细胞因子水平，且安全性良好；其中联合治疗56 d在炎症细胞因子调节方面更具优势。

Objective To explore the clinical efficacy of Kangfuyan Capsules combined with antibiotics in the treatment of pelvic pain caused by pelvic inflammatory disease(PID) and analyze their impacts on TCM syndrome scores and inflammatory cytokine levels in patients.Methods A total of 180 PID patients with pelvic pain who were admitted to Hangzhou Linping District Maternal and Child Health Care Hospital from October 2022 to February 2025 were randomly divided into a control group, short-term drug group, and long-term drug group, with 60 cases in each group. The control group was treated with Cefdinir Capsules; short-term drug group was given Kangfuyan Capsules for 28 days on the basis of the control group's treatment; long-term drug group was administered Kangfuyan Capsules for 56 days in combination with the control group's regimen. The clinical efficacy, TCM syndrome scores, C-reactive protein(CRP), interleukin-6(IL-6), interleukin-10(IL-10) levels, and incidence of adverse reactions were compared among the three groups. Results After treatment, the total effective rates of short-term drug group(90.00%) and long-term drug group(95.00%) were significantly higher than that of the control group(75.00%), with statistical differences(χ²=4.675, 9.412, all P<0.05), but there was no significant difference in the total effective rate between short-term drug group and long-term drug group(χ²=1.081, P>0.05).The scores of major TCM syndromes [(3.24±0.89) points] and minor TCM syndromes [(3.12±0.84) points] in short-term drug group were significantly lower than those in the control group [(5.37±1.16) points and(4.78±0.95) points, respectively], with statistical differences(t=11.280, 10.140, all P<0.05).The scores of major TCM syndromes [(3.07±0.72) points] and minor TCM syndromes [(2.74±0.71) points] in long-term drug group were also significantly lower than those in the control group(t=13.050, 13.320, all P<0.05), and the score of minor TCM syndromes in long-term drug group was lower than that in short-term drug group(t=2.676, P<0.05).The levels of CRP [(5.12±1.86) mg/L] and IL-6 [(14.42±3.75) pg/ml] in short-term drug group were significantly lower than those in the control group [CRP(8.25±2.41) mg/L, IL-6(20.16±4.38) pg/ml], with statistical differences(t=7.964, 7.711, all P<0.05), while the level of IL-10 [(29.84±5.16) pg/ml] was significantly higher than that in the control group [(24.35±4.52) pg/ml](t=6.199, P<0.05).The levels of CRP [(3.85±1.24) mg/L] and IL-6 [(10.26±3.02) pg/ml] in long-term drug group were significantly lower than those in the control group(t=12.580, 14.410, all P<0.05), and the level of IL-10 [(33.74±5.86) pg/ml] was significantly higher than that in the control group(t=9.828, P<0.05).Furthermore, the levels of CRP and IL-6 in long-term drug group were significantly lower than those in short-term drug group(t=4.401, 6.692, all P<0.05), and the level of IL-10 was significantly higher than that in short-term drug group(t=3.869, P<0.05).There was no significant difference in the incidence of adverse reactions among the control group(8.33%), short-term drug group(5.00%), and long-term drug group(10.00%)(χ²=1.084, P>0.05).Conclusion Kangfuyan Capsules combined with antibiotics have a significant efficacy in the treatment of PID-induced pelvic pain. They can improve the total effective rate, reduce TCM syndrome scores, and optimize inflammatory cytokine levels with good safety. Among them, the 56 days combined treatment is more advantageous in regulating inflammatory cytokines.